Trio of Firms Guide GSK’s $10.6bn US Cancer Drug Maker Buy

Why It Matters

The deal expands GSK’s oncology pipeline and adds high‑potential antibody‑drug conjugates, positioning the company for multi‑billion‑dollar revenue growth in lung cancer. It also signals continued consolidation in the biotech sector as large pharma seeks innovative assets to offset generic pressure.

Key Takeaways

• GSK to acquire Nuvalent for $10.6 bn cash
• Deal values Nuvalent at $124 per share, 40% premium
• Nuvalent’s lung‑cancer drugs could generate $3‑4 bn annual sales
• Davis Polk, Slaughter & May counsel GSK; Ropes & Gray counsel Nuvalent
• Transaction may dilute GSK EPS low single‑digit percent by 2028

Pulse Analysis

GSK’s purchase of Nuvalent marks a strategic push into next‑generation oncology, reinforcing its commitment to diversify beyond vaccines and traditional small‑molecule drugs. By securing a platform that houses the experimental antibody‑drug conjugate Ris‑Rez and two late‑stage lung‑cancer candidates, GSK aims to capture a share of the rapidly expanding immuno‑oncology market, where competitors are racing to launch blockbuster therapies. The cash‑heavy structure, funded by new and existing debt, reflects confidence in the deal’s ability to generate sustainable cash flow and offset the modest earnings‑per‑share dilution projected for 2026‑2028.

Nuvalent’s pipeline, anchored by zidesamtinib and neladalkib, targets non‑small cell lung cancer—a segment projected to exceed $10 bn in global sales within the next decade. Analysts estimate combined peak sales of $3‑4 bn, a figure that could elevate GSK’s oncology revenue by double‑digit percentages. Moreover, the acquisition provides GSK with a foothold in antibody‑drug conjugate technology, a modality gaining traction for its targeted delivery and reduced toxicity, potentially unlocking additional multi‑billion‑dollar opportunities as clinical data mature.

The advisory roster underscores the deal’s complexity: Davis Polk and Slaughter & May guide GSK, while Ropes & Gray represent Nuvalent, with financial advice from Leerink, Citi, and Centerview. Such a consortium highlights the high stakes of cross‑border pharma M&A, where legal, regulatory, and financing expertise must align to close multi‑billion‑dollar transactions efficiently. As GSK integrates Nuvalent, the market will watch how the combined entity leverages its expanded oncology suite to compete with peers like Pfizer and AstraZeneca, shaping the competitive landscape of cancer therapeutics for years to come.